74 related articles for article (PubMed ID: 12431023)
1. Ambrisentan (Myogen).
Billman GE
Curr Opin Investig Drugs; 2002 Oct; 3(10):1483-6. PubMed ID: 12431023
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and in vitro evaluation of ambrisentan analogues as potential endothelin receptor antagonists.
Xia J; Song J; Zhen L; Zhang X; Lei X; Zheng L; Wang Q; Sun H
Bioorg Med Chem Lett; 2011 Jul; 21(13):3894-7. PubMed ID: 21652209
[TBL] [Abstract][Full Text] [Related]
3. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension.
Kingman M; Ruggiero R; Torres F
Expert Opin Pharmacother; 2009 Aug; 10(11):1847-58. PubMed ID: 19601701
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas.
Mucke HA
IDrugs; 2009 Jun; 12(6):366-75. PubMed ID: 19517317
[TBL] [Abstract][Full Text] [Related]
5. Ambrisentan, a non-peptide endothelin receptor antagonist.
Vatter H; Seifert V
Cardiovasc Drug Rev; 2006; 24(1):63-76. PubMed ID: 16939634
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic evaluation of ambrisentan.
Buckley MS; Wicks LM; Staib RL; Kirejczyk AK; Varker AS; Gibson JJ; Feldman JP
Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):371-80. PubMed ID: 21299444
[TBL] [Abstract][Full Text] [Related]
7. Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension.
Halank M; Knudsen L; Seyfarth HJ; Ewert R; Wiedemann B; Kolditz M; Höffken G; Hoeper MM
Z Gastroenterol; 2011 Sep; 49(9):1258-62. PubMed ID: 21887662
[TBL] [Abstract][Full Text] [Related]
8. Ambrisentan.
Frampton JE
Am J Cardiovasc Drugs; 2011 Aug; 11(4):215-26. PubMed ID: 21623643
[TBL] [Abstract][Full Text] [Related]
9. Bladder endothelin-1 receptor binding of bosentan and ambrisentan.
Osano A; Yokoyama Y; Hayashi H; Itoh K; Okura T; Deguchi Y; Ito Y; Yamada S
J Pharmacol Sci; 2014; 124(1):86-91. PubMed ID: 24389822
[TBL] [Abstract][Full Text] [Related]
10. Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats.
Schiffrin EL; Turgeon A; Deng LY
Br J Pharmacol; 1997 Jul; 121(5):935-40. PubMed ID: 9222550
[TBL] [Abstract][Full Text] [Related]
11. Administration of a selective endothelin-a receptor antagonist (BSF 208075) improves hepatic warm ischemia/reperfusion injury in pigs.
Witzigmann H; Ludwig S; Escher E; Armann B; Gäbel G; Teupser D; Tannapfel A; Pietsch U; Hauss J; Uhlmann D
Transplant Proc; 2002 Sep; 34(6):2387-8. PubMed ID: 12270450
[No Abstract] [Full Text] [Related]
12. An endothelin antagonist for resistant hypertension.
Bharti B; Bharti S
Lancet; 2010 Feb; 375(9715):635; author reply 636-7. PubMed ID: 20171391
[No Abstract] [Full Text] [Related]
13. Role of ambrisentan (selective endothelin-A receptor antagonist) on cigarette smoke exposure induced cognitive impairment in Danio rerio.
Muthuraman A; Nafisa K; Sowmya MS; Arpitha BM; Choedon N; Sandy CD; Rishitha N; Johurul I
Life Sci; 2019 Apr; 222():133-139. PubMed ID: 30844374
[TBL] [Abstract][Full Text] [Related]
14. Interaction of ambrisentan and phenprocoumon in patients with pulmonary hypertension.
Sommer N; Grimminger J; Ghofrani HA; Tiede H
Pulm Pharmacol Ther; 2014 Jun; 28(1):87-89. PubMed ID: 24650719
[No Abstract] [Full Text] [Related]
15. EndothelinA receptor antagonist BSF-208075 causes immune modulation and neuroprotection after stroke in gerbils.
Hauck EF; Hoffmann JF; Heimann A; Kempski O
Brain Res; 2007 Jul; 1157():138-45. PubMed ID: 17506996
[TBL] [Abstract][Full Text] [Related]
16. Effect of the novel endothelin(A) receptor antagonist LU 208075 on contraction and relaxation of isolated rat basilar artery.
Vatter H; Zimmermann M; Jung C; Weyrauch E; Lang J; Seifert V
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():408S-413S. PubMed ID: 12193134
[TBL] [Abstract][Full Text] [Related]
17. Effects of multiple doses of ambrisentan on the pharmacokinetics of a single dose of digoxin in healthy volunteers.
Richards DB; Spence R; Mandagere A; Henderson LS; Magee MH
J Clin Pharmacol; 2011 Jan; 51(1):102-6. PubMed ID: 20350954
[No Abstract] [Full Text] [Related]
18. An endothelin antagonist for resistant hypertension.
Dhaun N; Goddard J; Webb DJ
Lancet; 2010 Feb; 375(9715):635; author reply 636-7. PubMed ID: 20171390
[No Abstract] [Full Text] [Related]
19. An endothelin antagonist for resistant hypertension.
Naunton M
Lancet; 2010 Feb; 375(9715):636; author reply 636-7. PubMed ID: 20171393
[No Abstract] [Full Text] [Related]
20. Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis.
Kappes L; Amer RL; Sommerlatte S; Bashir G; Plattfaut C; Gieseler F; Gemoll T; Busch H; Altahrawi A; Al-Sbiei A; Haneefa SM; Arafat K; Schimke LF; Khawanky NE; Schulze-Forster K; Heidecke H; Kerstein-Staehle A; Marschner G; Pitann S; Ochs HD; Mueller A; Attoub S; Fernandez-Cabezudo MJ; Riemekasten G; Al-Ramadi BK; Cabral-Marques O
Sci Rep; 2020 Sep; 10(1):15931. PubMed ID: 32985601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
